Breaking Finance News

Ascendis Pharma A S (NASDAQ:ASND) has been upgraded to Hold in a report by Zacks Investment Research today.

Zacks Investment Research has upgraded Ascendis Pharma A S (NASDAQ:ASND) to Hold in a report released on 11/28/2016.

Yesterday Ascendis Pharma A S (NASDAQ:ASND) traded -0.61% lower at $20.51. Ascendis Pharma A S’s 50-day moving average is $0.00 and its 200-day moving average is $0.00. With the last stock price up 0.00% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.03% over the same period. Volume of trade was down over the average, with 58,181 shares of ASND changing hands under the typical 75,372

See Chart Below

Ascendis Pharma A S (NASDAQ:ASND)

Ascendis Pharma A S has a with a one year low of $11.92 and a 52 week high of $21.79 The company’s market cap is currently $0.

General Information About Ascendis Pharma A S (NASDAQ:ASND)

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop a pipeline of long-acting prodrug therapies that address markets with unmet medical needs. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications. In addition to TransCon hGH, the Company has developed a pipeline of long-acting prodrug product candidates, such as TransCon Treprostinil for the treatment of pulmonary arterial hypertension (PAH), TransCon Peptides for the treatment of diabetes and TransCon Ranibizumab for the treatment of ophthalmology. The Company's subsidiaries include Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma and Endocrinology Division A/S (Denmark).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.